Who
Diantha Duvall
CFO
Company insider
Files Form 4 as: CFO, Curis; Chief Financial Officer, Genocea Biosciences; Chief Accounting Officer, Bioverativ.
In numbers
- Trades disclosed
- 54
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $60K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 14 Feb 2017
- Last trade
- 7 Jul 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 9 Jul 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $255K48,285 at $5.29 | filing |
| 7 Jul 2026filed 9 Jul 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $255K48,285 at $5.29 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS CurisBiotechnology | SEC FORM 4 Code C | —66,666 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code C | —50 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code C | —50 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS CurisBiotechnology | SEC FORM 4 Code C | —66,666 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —50 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,666 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,666 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —50 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,666 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,666 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,666 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,666 | filing |
| 20 May 2025filed 22 May 2025 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $423K135,000 at $3.13 | filing |
| 28 Jan 2025filed 30 Jan 2025 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $47K15,000 at $3.13 | filing |
| 21 May 2024filed 23 May 2024 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $453K39,000 at $11.62 | filing |
| 20 Jan 2023filed 24 Jan 2023 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 2 Jun 2022filed 3 Jun 2022 | Genocea Biosciences | SEC FORM 4 Sold | $811,355 at $0.06 | filing |
| 26 May 2022filed 26 May 2022 | Genocea Biosciences | SEC FORM 4 Sold | $1,95324,407 at $0.08 | filing |
News
No headline names them, or the companies they trade most, lately.